Delcath Systems (NASDAQ:DCTH) Stock Rating Upgraded by StockNews.com

Delcath Systems (NASDAQ:DCTH) was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating in a research note issued to investors on Friday.

Other equities analysts also recently issued research reports about the company. Craig Hallum started coverage on Delcath Systems in a report on Friday, June 28th. They set a “buy” rating and a $18.00 price target on the stock. HC Wainwright reiterated a “buy” rating and issued a $22.00 target price on shares of Delcath Systems in a research note on Tuesday, August 6th. Finally, Stephens reissued an “overweight” rating and set a $25.00 target price on shares of Delcath Systems in a research report on Tuesday, August 6th.

Delcath Systems Trading Up 3.0 %

Shares of NASDAQ:DCTH opened at $9.14 on Friday. The stock has a market capitalization of $253.83 million, a PE ratio of -3.45 and a beta of 0.78. Delcath Systems has a 1 year low of $2.25 and a 1 year high of $11.74. The firm has a fifty day moving average price of $8.92 and a 200 day moving average price of $7.26.

Delcath Systems (NASDAQ:DCTH) last released its quarterly earnings results on Monday, August 5th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.12). Delcath Systems had a negative return on equity of 312.48% and a negative net margin of 474.22%. The company had revenue of $7.77 million for the quarter, compared to the consensus estimate of $5.00 million. During the same quarter last year, the company posted ($0.58) EPS. On average, sell-side analysts forecast that Delcath Systems will post -1.67 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Levin Capital Strategies L.P. grew its stake in shares of Delcath Systems by 12.2% in the first quarter. Levin Capital Strategies L.P. now owns 54,969 shares of the company’s stock worth $262,000 after acquiring an additional 5,969 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new stake in Delcath Systems in the 2nd quarter worth $370,000. Renaissance Technologies LLC bought a new position in shares of Delcath Systems during the 2nd quarter worth about $694,000. Marshall Wace LLP raised its position in shares of Delcath Systems by 7.0% during the second quarter. Marshall Wace LLP now owns 92,731 shares of the company’s stock valued at $776,000 after buying an additional 6,066 shares during the last quarter. Finally, ADAR1 Capital Management LLC bought a new stake in shares of Delcath Systems in the fourth quarter valued at about $962,000. 61.12% of the stock is currently owned by institutional investors and hedge funds.

About Delcath Systems

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.